Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Net Cash Flow (2020 - 2025)

Rapid Micro Biosystems' Net Cash Flow history spans 6 years, with the latest figure at $613000.0 for Q3 2025.

  • For Q3 2025, Net Cash Flow rose 104.07% year-over-year to $613000.0; the TTM value through Sep 2025 reached -$3.1 million, down 77.84%, while the annual FY2024 figure was -$7.3 million, 162.43% down from the prior year.
  • Net Cash Flow for Q3 2025 was $613000.0 at Rapid Micro Biosystems, up from -$654000.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $119.5 million in Q3 2021 and bottomed at -$115.9 million in Q1 2022.
  • The 5-year median for Net Cash Flow is -$1.9 million (2024), against an average of -$576263.2.
  • The largest annual shift saw Net Cash Flow skyrocketed 1430.3% in 2021 before it crashed 1112.42% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$41.2 million in 2021, then surged by 102.99% to $1.2 million in 2022, then plummeted by 59.5% to $499000.0 in 2023, then plummeted by 1112.42% to -$5.1 million in 2024, then skyrocketed by 112.13% to $613000.0 in 2025.
  • Per Business Quant, the three most recent readings for RPID's Net Cash Flow are $613000.0 (Q3 2025), -$654000.0 (Q2 2025), and $2.0 million (Q1 2025).